ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TARA ArTara Therapeutics, Inc.

交易中 06-18 09:57:55 EDT

4.16

+0.09

+2.21%

最高4.20	最低4.12	成交量9.13万
今开4.13	昨收4.07	日振幅1.96%
总市值2.34亿	流通市值2.06亿	总股本5,620万
成交额37.92万	换手率0.18%	流通股本4,955万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TARA","market":"US","secType":"STK","nameCN":"ArTara Therapeutics, Inc.","latestPrice":4.16,"timestamp":1781791053071,"preClose":4.07,"halted":0,"volume":91323,"delay":0,"changeRate":0.022113022113022077,"floatShares":49554200,"shares":56204200,"eps":-1.3409,"marketStatus":"交易中","change":0.09,"latestTime":"06-18 09:57:55 EDT","open":4.13,"high":4.2,"low":4.1201,"amount":379243.323387,"amplitude":0.019631,"askPrice":4.16,"askSize":347,"bidPrice":4.15,"bidSize":332,"shortable":3,"etf":0,"ttmEps":-1.3409,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1781812800000},"marketStatusCode":2,"adr":0,"listingDate":1413950400000,"exchange":"NASDAQ","adjPreClose":4.07,"preHourTrading":{"tag":"盘前","latestPrice":4.14,"preClose":4.07,"latestTime":"09:29 EDT","volume":309,"amount":1278.169848,"timestamp":1781789399999,"change":0.07,"changeRate":0.017199,"amplitude":0.067617},"postHourTrading":{"tag":"盘后","latestPrice":4.07,"preClose":4.07,"latestTime":"19:26 EDT","volume":7687,"amount":31286.8038,"timestamp":1781738773941,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.665625,"impliedVol":1.7633,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/TARA","defaultTab":"news","newsList":[{"id":"1185388119","title":"Protara Therapeutics Inc. 计划于2026年下半年在BCG初治患者中启动Advanced-3注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1185388119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185388119?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:12","pubTimestamp":1778843558,"startTime":"0","endTime":"0","summary":"Protara Therapeutics Inc. 正稳步推进其临床开发计划，目标是在2026年下半年，针对BCG初治患者群体，启动其关键的Advanced-3注册试验。这一进展标志着公司在推进其候选疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117853813","title":"Protara Therapeutics公布积极更新数据：TARA-002治疗BCG初治型NMBC的二期试验完全入组队列12个月结果展现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1117853813","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117853813?lang=zh_cn&edition=full","pubTime":"2026-05-15 19:02","pubTimestamp":1778842941,"startTime":"0","endTime":"0","summary":"Protara Therapeutics公司公布了其正在进行的二期Advanced-2试验的最新积极数据。数据显示，针对BCG初治型非肌层浸润性膀胱癌（NMBC）患者，TARA-002治疗在完全入组的患者队列中，展现了长达12个月的持久治疗反应。\n此次更新的12个月数据进一步验证了TARA-002在该患者群体中的潜力。试验结果持续显示出良好的疗效信号，为后续临床开发提供了有力支持。该消息增强了市场对Protara Therapeutics核心管线产品前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181960953","title":"Protara Therapeutics将在美国泌尿外科学会年会公布Tara-002治疗BCG初治NMIBC患者的2期Advanced-2试验最新12个月中期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1181960953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181960953?lang=zh_cn&edition=full","pubTime":"2026-04-28 04:06","pubTimestamp":1777320388,"startTime":"0","endTime":"0","summary":"Protara Therapeutics公司宣布，将于美国泌尿外科学会年度会议上披露其候选药物Tara-002针对BCG初治非肌层浸润性膀胱癌（NMIBC）患者的2期Advanced-2临床试验的最新12个月中期研究结果。\n此次公布的数据将包含治疗组在12个月时间点的最新疗效指标和安全性评估，为这款创新疗法的临床开发进展提供重要依据。该研究旨在评估Tara-002在这一患者群体中的潜在治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148456076","title":"ArTara Therapeutics预计2026年下半年完成BCG无应答队列入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1148456076","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148456076?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:17","pubTimestamp":1773145068,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics公司宣布，其针对BCG（卡介苗）无应答患者的Advanced-2临床试验队列，预计将于2026年下半年完成患者招募工作。这一进展标志着该公司在泌尿系统肿瘤治疗领域的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168651837","title":"ArTara Therapeutics公司按计划将于2026年下半年启动针对BCG初治患者的Advanced-3注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1168651837","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168651837?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:13","pubTimestamp":1773144800,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics公司正稳步推进其临床开发计划，预计在2026年下半年正式启动针对BCG初治患者群体的Advanced-3阶段注册试验。这一关键进展标志着公司在泌尿系统肿瘤治疗领域取得了重要突破。该试验旨在评估创新疗法对未接受过BCG治疗患者的疗效与安全性，其设计遵循严格的注册标准，为后续商业化申请奠定基础。若试验结果达到预期目标，将为该患者群体提供全新的治疗选择，同时有望显著提升公司在专科治疗领域的市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131938474","title":"Protara Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1131938474","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131938474?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:13","pubTimestamp":1773144782,"startTime":"0","endTime":"0","summary":"Protara Therapeutics（股票代码：TARA）近日披露了2025年第四季度及全年财务报告，同时向市场同步了公司最新业务动态。此次公告涵盖了公司在财务表现和研发进程方面的关键信息，为投资者提供了全面的运营洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128819293","title":"Protara Therapeutics Inc：安全性及耐受性表现良好，未出现3级或以上治疗相关不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1128819293","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128819293?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:11","pubTimestamp":1771884672,"startTime":"0","endTime":"0","summary":"Protara Therapeutics Inc（简称Protara）最新研究数据显示，其治疗方案展现出良好的安全性与耐受性特征。在临床试验过程中，未观察到任何3级或更高级别的治疗相关不良事件发生。这一结果进一步支持了该疗法在临床应用中的可靠性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139200600","title":"ArTara Therapeutics, Inc.：按计划推进于2026年下半年启动针对BCG初治患者的Advanced-3期注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1139200600","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139200600?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:11","pubTimestamp":1771884671,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics, Inc. 宣布，公司研发管线进展顺利，仍按照既定时间表推进关键临床试验。目前预计在2026年下半年，正式启动针对BCG初治患者群体的Advanced-3期注册临床试验。这一试验的启动是公司药物开发路径上的一个重要里程碑，标志着其核心候选产品向潜在获批上市又迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183960066","title":"ArTara Therapeutics公司：预计2026年下半年完成BCG无应答队列的Advanced-2试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1183960066","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183960066?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:10","pubTimestamp":1771884619,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics公司宣布，其针对BCG无应答患者队列的Advanced-2临床试验，预计将于2026年下半年完成全部患者入组工作。该试验旨在评估公司在研疗法对于此类难治性患者群体的有效性与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166559010","title":"Tara-002在BCG无应答非肌层浸润性膀胱癌中展现68%的六个月完全缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1166559010","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166559010?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:06","pubTimestamp":1771884371,"startTime":"0","endTime":"0","summary":"ArTara Therapeutics, Inc.旗下疗法Tara-002在针对BCG无应答型非肌层浸润性膀胱癌的临床研究中，取得了令人瞩目的成果。数据显示，在为期六个月的评估期内，该疗法的完全缓解率达到了68%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106320216","title":"Protara Therapeutics启动静脉氯化胆碱三期关键性Thrive-3试验 首位长期肠外营养患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1106320216","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106320216?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:09","pubTimestamp":1767791396,"startTime":"0","endTime":"0","summary":"生物制药公司Protara Therapeutics宣布，其针对长期肠外营养患者开展的静脉氯化胆碱三期注册性Thrive-3临床试验已完成首位患者给药。该试验旨在评估药物对肠衰竭相关肝损伤的疗效，标志着公司核心管线推进的重要里程碑。基于胆碱缺乏与肝脂肪变性病理机制的紧密关联，此次试验设计包含多重疗效终点，包括肝脏脂肪含量影像学评估与生化指标改善等核心维度。随着首位患者给药完成，后续将加速推进多中心临床入组工作，为潜在的新药申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518315746","title":"Protara Therapeutics(TARA.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518315746","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518315746?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696881,"startTime":"0","endTime":"0","summary":"Protara Therapeutics(TARA.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价22.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518279833","title":"Protara Therapeutics, Inc.盘中异动 快速下跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518279833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518279833?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:31","pubTimestamp":1741617064,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时31分，Protara Therapeutics, Inc.股票出现异动，股价大幅下跌5.22%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3458.16%、731.26%、518.39%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223105abf312bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223105abf312bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517942764","title":"Protara Therapeutics, Inc.盘中异动 急速上涨5.36%报3.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517942764","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517942764?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:11","pubTimestamp":1741194675,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日01时11分，Protara Therapeutics, Inc.股票出现波动，股价急速拉升5.36%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.16%。其相关个股中，Chimerix, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Celularity Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为930.77%、302.46%、287.48%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306011116963b0023&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306011116963b0023&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TARA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517912526","title":"Protara Therapeutics(TARA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.48美元，前值为-0.90美元，预期值为-0.56美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912526","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517912526?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:41","pubTimestamp":1741182093,"startTime":"0","endTime":"0","summary":"Protara Therapeutics(TARA.US)：2024年Q4财报实现营收0美元，前值为0美元；每股收益为-0.48美元，前值为-0.90美元，预期值为-0.56美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05214148547481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154035416","title":"Protara Therapeutics第四季度每股收益$(0.48)，优于预期的$(0.56)","url":"https://stock-news.laohu8.com/highlight/detail?id=1154035416","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154035416?lang=zh_cn&edition=full","pubTime":"2025-03-05 21:20","pubTimestamp":1741180844,"startTime":"0","endTime":"0","summary":"Protara Therapeutics 报告季度每股亏损$，优于分析师一致预期的$，提高了14.29%。相比去年同期每股亏损$，这是一个46.67%的增加。以上内容来自Benzinga Earnings专栏，原文如下：Protara $Therapeutics$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 14.29 percent. This is a 46.67 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516777546","title":"Protara Therapeutics, Inc.盘中异动 急速跳水5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516777546?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:36","pubTimestamp":1741099007,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时36分，Protara Therapeutics, Inc.股票出现波动，股价急速跳水5.52%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Exicure, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1087.57%、1073.51%、425.82%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223648abe7f184&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223648abe7f184&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512192635","title":"Protara Therapeutics, Inc.盘中异动 临近收盘大幅下跌5.05%报3.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512192635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512192635?lang=zh_cn&edition=full","pubTime":"2025-02-19 04:51","pubTimestamp":1739911862,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日04时51分，Protara Therapeutics, Inc.股票出现异动，股价快速下跌5.05%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.72%。其相关个股中，Aditxt, Inc.、Allogene Therapeutics, Inc.、Solid Biosciences Inc.涨幅较大，Aditxt, Inc.、Moleculin Biotech, Inc.、Solid Biosciences Inc.较为活跃，换手率分别为966.91%、222.60%、175.32%，振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Abvc Biopharma, Inc.、Allogene Therapeutics, Inc.，振幅分别为148.75%、92.00%、79.17%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045102a24af961&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219045102a24af961&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TARA","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511359526","title":"Protara Therapeutics, Inc.盘中异动 早盘急速上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511359526","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511359526?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:41","pubTimestamp":1739457707,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时41分，Protara Therapeutics, Inc.股票出现异动，股价快速拉升5.18%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Pliant Therapeutics, Inc.涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1036.64%、998.14%、201.49%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Moleculin Biotech, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 ，振幅分别为69.33%、56.19%、32.86%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224147a244adb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224147a244adb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TARA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509396203","title":"Protara Therapeutics, Inc.盘中异动 早盘股价大跌5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509396203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509396203?lang=zh_cn&edition=full","pubTime":"2025-02-06 23:24","pubTimestamp":1738855490,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日23时24分，Protara Therapeutics, Inc.股票出现异动，股价大幅下挫5.41%。Protara Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为5351.35%、1260.89%、131.39%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为103.10%、39.93%、36.09%。Protara Therapeutics, Inc.公司简介：Protara Therapeutics Inc 致力于为癌症和罕见疾病患者寻找和推进变革性疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232450abc4e10d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206232450abc4e10d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TARA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protaratx.com","stockEarnings":[{"period":"1week","weight":0.0767},{"period":"1month","weight":-0.1152},{"period":"3month","weight":-0.2321},{"period":"6month","weight":-0.2277},{"period":"1year","weight":0.3301},{"period":"ytd","weight":-0.2364}],"compareEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.123},{"period":"6month","weight":0.0887},{"period":"1year","weight":0.24},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protara Therapeutics, Inc.最初于2006年3月24日在特拉华州注册成立。该公司是一家总部位于纽约市的临床阶段生物制药公司，致力于推进治疗癌症和罕见疾病的变革性疗法。该公司的产品组合包括两个利用TARA-002的开发项目，TARA-002是一种基于广泛免疫增强剂OK-432的研究性细胞疗法，该药物最初被日本厚生省授予上市许可，作为一种免疫增强型癌症治疗剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.112142},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.009772},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.05879},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.092385},{"month":5,"riseRate":0.25,"avgChangeRate":0.037834},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030939},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.047236},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.03111},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.021366},{"month":10,"riseRate":0.454545,"avgChangeRate":0.012653},{"month":11,"riseRate":0.833333,"avgChangeRate":0.1444},{"month":12,"riseRate":0.5,"avgChangeRate":0.040004}],"exchange":"NASDAQ","name":"ArTara Therapeutics, Inc.","nameEN":"ArTara Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ArTara Therapeutics, Inc.(TARA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ArTara Therapeutics, Inc.,TARA,ArTara Therapeutics, Inc.股票,ArTara Therapeutics, Inc.股票老虎,ArTara Therapeutics, Inc.股票老虎国际,ArTara Therapeutics, Inc.行情,ArTara Therapeutics, Inc.股票行情,ArTara Therapeutics, Inc.股价,ArTara Therapeutics, Inc.股市,ArTara Therapeutics, Inc.股票价格,ArTara Therapeutics, Inc.股票交易,ArTara Therapeutics, Inc.股票购买,ArTara Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ArTara Therapeutics, Inc.(TARA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ArTara Therapeutics, Inc.(TARA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}